Perflexane
CAS 355-42-0
Perflexane (CAS 355-42-0) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Perflexane used for in pharmaceutical contexts?
Perflexane (CAS 355-42-0) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Perflexane?
No adverse-event association or SIDER side-effect rows are rendered for Perflexane in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Perflexane also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Perfluorohexane with EU status "permitted".
What clinical phase is Perflexane in?
Perflexane is rendered with ChEMBL max phase 4 (approved).